Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 5, 2014, Pages 757-767

  Ku, Bo Mi ^a   Kim, Se Jin ^a   Kim, Nayeon ^b   Hong, Dongwan ^a   Choi, Yong Bock ^a   Lee, Seon Hyeong ^a   Gong, Young Dae ^b   Kim, Soo Youl ^a  

^a National Cancer Center   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

p53; Renal cell carcinoma; TGase 2 inhibitor; Transglutaminase 2

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; GK 921; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 INHIBITOR; PROTEIN P53; QUINOXALINE DERIVATIVE; SULFORHODAMINE B; UNCLASSIFIED DRUG; VASCULOTROPIN; [3 (PHENYLETHYNYL) 2 [2 (PYRIDIN 2 YL)ETHOXY]PYRIDO[3,2 B]PYRAZINE];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HUMANS; MICE; PYRAZINES; TRANSGLUTAMINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901592302     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1623-5     Document Type: Article

References (33)

1. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data setsupdate. Nucl Acids Res 41(Database issue):D991-D995. doi:10.1093/nar/gks1193
2. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T (2008) Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 7(5):699-708. doi:10.4161/cbt.7.5.5712
3. Choueiri TK (2011) VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. Curr Clin Pharmacol 6(3):164-168
4. Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, Murata K, Kim SJ, Lautsch N, Kobayashi KS, Shirai T, Karin M, Nakanishi M (2012) TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci USA 109(4):E177-E186. doi:10.1073/pnas.1119296109
5. Gong YD, Lee T (2010) Combinatorial syntheses of five-membered ring heterocycles using carbon disulfide and a solid support. J Comb Chem 12(4):393-409. doi:10.1021/cc100049u
6. Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Greco F (2013) Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI oncology research consortium. Cancer Invest 31(5):323-329. doi:10.3109/07357907.2013.789900
7. Han BG, Cho JW, Cho YD, Jeong KC, Kim SY, Lee BI (2010) Crystal structure of human transglutaminase 2 in complex with adenosine triphosphate. Int J Biol Macromol 47(2):190-195. doi:10.1016/j.ijbiomac.2010.04.023
8. Iismaa SE, Holman S, Wouters MA, Lorand L, Graham RM, Husain A (2003) Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases. Proc Natl Acad Sci USA 100(22):12636-12641. doi:10.1073/pnas.1635052100 (Pubitemid 37339951)
9. Jin X, Stamnaes J, Klock C, DiRaimondo TR, Sollid LM, Khosla C (2011) Activation of extracellular transglutaminase 2 by thioredoxin. J Biol Chem 286(43):37866-37873. doi:10.1074/jbc.M111.287490
10. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11(16):5730-5739. doi:10.1158/1078-0432.CCR-04-2225 (Pubitemid 41170297)
11. Kim DS, Park S, Nam BH, Kim IH, Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-κB inactivation. Cancer Res 66(22):10936-10943. doi:10.1158/0008-5472.CAN-06-1521 (Pubitemid 44876992)
12. Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH, Ahn ER, Shin JE, Lee BI, Lee H, Hong KM, Kim SY (2011a) Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene 30(48):4780-4790. doi:10.1038/onc.2011.183
13. Kim SJ, Kim KH, Ahn ER, Yoo BC, Kim SY (2011b) Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival. Amino Acids. doi:10.1007/s00726-011-1089-6
14. Ku BM, Kim DS, Kim KH, Yoo BC, Kim SH, Gong YD, Kim SY (2013) Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J. doi:10.1096/fj.12-224220
15. Lai TS, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, Strittmatter WJ, Greenberg CS (2008) Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol 15(9):969-978. doi:10.1016/j.chembiol.2008.07.015
16. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY (2004) Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J Biol Chem 279(51):53725-53735. doi:10.1074/jbc. M407627200 (Pubitemid 40051881)
17. Lee SH, Kim N, Kim SJ, Song J, Gong YD, Kim SY (2013) Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. J Cancer Res Clin Oncol 139(8):1279-1294. doi:10.1007/s00432-013-1433-1
18. Lentini A, Tabolacci C, Provenzano B, Rossi S, Beninati S (2010) Phytochemicals and protein-polyamine conjugates by transglutaminase as chemopreventive and chemotherapeutic tools in cancer. Plant Physiol Biochem 48(7):627-633. doi:10.1016/j.plaphy.2010.02.010
19. Lipworth L, Tarone RE, McLaughlin JK (2006) The epidemiology of renal cell carcinoma. J Urol 176(6 Pt 1):2353-2358. doi:10.1016/j.juro.2006.07.130 (Pubitemid 44665976)
20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124. doi:10.1056/NEJMoa065044 (Pubitemid 46089672)
21. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722-731. doi:10.1056/NEJMoa1303989
22. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, Song J (2006) Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem 281(25):17457-17465. doi:10.1074/jbc.M601857200
23. Pardin C, Gillet SM, Keillor JW (2006) Synthesis and evaluation of peptidic irreversible inhibitors of tissue transglutaminase. Bioorg Med Chem 14(24):8379-8385. doi:10.1016/j.bmc.2006.09.011 (Pubitemid 44667551)
24. Park S, Kim JM, Kim DS, Kim IH, Kim SY (2006) Transglutaminase 2 mediates polymer formation of I-κBα through C-terminal glutamine cluster. J Biol Chem 281(46):34965-34972. doi:10.1074/jbc.M604150200 (Pubitemid 46036535)
25. Pirrotta MT, Bernardeschi P, Fiorentini G (2011) Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 18(11):1651-1657. BSP/CMC/E-Pub/2011/111
26. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12(1):206-212 (Pubitemid 24020641)
27. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6(1):1-6 (Pubitemid 38391943)
28. Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115(2):232- 245. doi:10.1016/j.pharmthera.2007.05.003
29. Siegel M, Xia J, Khosla C (2007) Structure-based design of α-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem 15(18):6253-6261. doi:10.1016/j.bmc.2007.06. 020 (Pubitemid 47088951)
30. Sohn J, Kim TI, Yoon YH, Kim JY, Kim SY (2003) Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest 111(1):121-128. doi:10.1172/JCI15937 (Pubitemid 36134855)
31. Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C, Sollid LM (2010) Redox regulation of transglutaminase 2 activity. J Biol Chem 285(33):25402-25409. doi:10.1074/jbc.M109.097162
32. Suh GY, Ham HS, Lee SH, Choi JC, Koh WJ, Kim SY, Lee J, Han J, Kim HP, Choi AM, Kwon OJ (2006) A peptide with anti-transglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice. Exp Lung Res 32(1-2):43-53. doi:10.1080/01902140600691514 (Pubitemid 43732306)
33. Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G (2009) High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 9:152. doi:10.1186/1471-2407-9-152